Sign In
Last checked at 
1 Jun 2026 15:30
1 June 2026
Futura Medical plc
("Futura", "the Group" or the "Company")
Block Listing Six Monthly Return
Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).
Name of applicant: | Futura Medical Plc | |||
Name of scheme(s): | Unapproved Share Option Scheme Unapproved Share Incentive Scheme EMI Share Option Scheme LTIP Scheme | |||
Period of return: | From: | 9 December 2025 | To: | 31 May 2026 |
Balance of unallotted securities under scheme(s) from previous return: | 16,237,570 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | USOS: nil USIS: nil EMI: nil LTIP: nil | |||
Less: Number of securities issued/allotted under scheme(s) during period: | USOS: nil USIS: nil EMI: nil LTIP: 207,096
| |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 16,030,474 | |||
Number and class of securities originally admitted and the date of admission | USOS Total: 3,882,912 814,424 25 May 2011 1,202,280 8 October 2013 1,466,208 25 May 2017 400,000 30 May 2018
USIS Total: 425,000 425,000 30 November 2018
EMI Total: 8,112,088 1,520,576 25 May 2011 1,467,720 8 October 2013 1,893,792 25 May 2017 790,000 30 May 2018 1,340,000 30 November 2018 1,100,000 2 February 2023
LTIP Total: 15,035,617 4,444,942 2 February 2023 10,590,675 3 November 2023
| |||
Contacts:
Futura Medical plc
| Alex Duggan Chief Executive Officer Angela Hildreth Finance Director and COO
| investor.relations@futuramedical.com +44 (0)1483 685 670 www.futuramedical.com
|
Panmure Liberum Nominated Adviser and Broker | Emma Earl, Will Goode, Mark Rogers (Corporate Finance)
| +44 (0)20 3100 2000
|
| ||
Turner Pope Investments (TPI) Ltd - Broker | Guy McDougall, Andrew Thacker | +44 (0) 20 3657 0050 |
| ||
Alma Strategic Communications | Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters | +44 (0)20 3405 0205 futura@almastrategic.com |
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative, consumer-focused, sexual health products, including lead product Eroxon® and development projects WSD4000 and Eroxon® Intense. Our core strength lies in our research, development, regulatory and business development expertise in developing innovative, clinically proven, insight-led and effective products to support our customers in the growing sexual health market.
Sexual health issues are prevalent globally in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. 60% of women experience at least one symptom of impaired sexual response or function in a twelve months period, with only one in four women seeking professional help and remaining chronically underserved.
Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection fast, addresses significant unmet needs in the ED market. Multiple license or distribution partnerships are in place for Eroxon®, across major consumer markets.
WSD4000 is a project name for our development female sexual health portfolio, starting with the creation of a range of topical gels under our unique platform technology, specifically designed to treat symptoms of sexual dysfunction in women. There is currently no known regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal, lubrication and ability to orgasm.
Follow the stocks
